nesvacumab (REGN910/ SAR307746)

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Solid Tumors

Phase 1

Study of Nesvacumab (REGN910/ SAR307746)

CompletedNCT01271972

Regeneron PharmaceuticalsSolid Tumors

Start: 2011-01-31End: 2015-05-31Updated: 2015-06-16

Nesvacumab (REGN910/ SAR307746) and Aflibercept (Ziv-aflibercept in the U.S.) in Patients With Advanced Solid Malignancies

CompletedNCT01688960

Regeneron PharmaceuticalsSolid Tumors

Start: 2012-10-31End: 2014-11-30Updated: 2015-03-17

Related Papers

A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.

Journal of Clinical Oncology2014-05-204 citations

Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.

Journal of Clinical Oncology2014-05-202 citations